Bristol Myers Squibb SWOT Analysis, Competitors & USP

Posted in Pharma and Healthcare, Total Reads: 10418

SWOT analysis of Bristol Myers Squibb analyses the brand/company with its strengths, weaknesses, opportunities & threats. Bristol Myers Squibb is one of the leading brands in the pharma and healthcare sector. In addition to SWOT Analysis, the table below also lists the top Bristol Myers Squibb competitors and elaborates Bristol Myers Squibb segmentation, targeting, positioning & USP.

Bristol Myers Squibb

Parent Company

Bristol Myers Squibb

Category

Biopharmaceuticals

Sector

Pharma and Healthcare

Tagline/ Slogan

Together we can prevail

USP

Bristol-Myers Squibb is a global BioPharma company focused to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Bristol Myers Squibb STP

Segment

Diseases such as cancer, cardiovascular disease, diabetes, hepatitis B, HIV/AIDS, rheumatoid arthritis and psychiatric disorders

Target Group

Healthcare professionals, doctors, pharmacists

Positioning

Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Bristol Myers Squibb SWOT Analysis

Strengths

Below is the Strengths, Weaknesses, Opportunities & Threats (SWOT) Analysis of Bristol Myers Squibb. Strengths are:

1.Deliver new medicines regularly

2. Provide free medications to qualifying patients with financial problems in the U.S.

3. Employ 44000 people all over world, strong global footprint

4. Corporate strategy with the acquisition of many other companies

5. String of new technologies, alliances has strengthened the brand

6. Co-development and co-commercialization agreements with companies have boosted image

Weaknesses

Here are the weaknesses in the Bristol Myers Squibb SWOT Analysis:

1.Strong dependence on working with third parties to improve and enhance abilities

2. Substantial drop in sales for two key drugs: Plavix, a blood thinner, and Pravachol, a cholesterol-lowering drug.

3. Company layoffs and post retirement plans may affect employee relations.

Opportunities

Following are the Opportunities in Bristol Myers Squibb SWOT Analysis:

1. Security technologies to make packaging and products less vulnerable to counterfeiting and to secure their movement within the supply chain

2. An integrated team addresses counterfeiting, product tampering, theft and diversion issues

3. Expand access to its products through strategic acquisitions & partnerships.

Threats

The threats in the SWOT Analysis of Bristol Myers Squibb are as mentioned:

1. The company acquires biotech companies, technology and expertise and hence a threat to its culture is infused ever more deeply.

2. Counterfeit drugs and product tampering, theft or diversion represent a threat

3. Pricing  pressures

4. Global economic slowdown

Bristol Myers Squibb Competition

Competitors

Below are the top 6 Bristol Myers Squibb competitors:

1.AstraZeneca

2.Roche Holding

3.Novartis

4.Merck & Co.

5.Biogen

6.Teva Pharmaceutical


The brandguide table above concludes the Bristol Myers Squibb SWOT analysis along with its marketing and brand parameters.

Similar analysis has also been done for the competitors of the company belonging to the same category, sector or industry.

Browse marketing analysis of more brands and companies similar to Bristol Myers Squibb. The BrandGuide section covers SWOT Analysis, USP, STP & Competition of more than 6000 brands from over 20 categories.

Search & Explore : BrandGuide


The brand names and other brand information used in the BrandGuide section are properties of their respective companies. The companies are not associated with MBASkool in any way. The brand names are used purely for educational/academic purpose only. Utmost care has been taken in the analysis of the brands. However, if you find any ambiguity kindly help us improve.

Edit the Brand or Add a New One : Contribute to BrandGuide
Share this Page on:
Facebook ShareTweetShare on G+Share on Linkedin